Market Overview

Teva Announces Signing of New $3B Syndicated Revolving Credit Line

Related TEVA
News Of Clinical Hold For Fasinumab Weighs On Regeneron, Teva Shares
Punishment For This Healthcare ETF Could Create Opportunity
FDA accepts Teva's resubmitted application for deutetrabenazine; action date April 3 (Seeking Alpha)

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it has entered into a new five-year, $3.0 billion unsecured revolving credit facility, which replaces its existing $2.5 billion credit facility.

Posted-In: News Financing


Related Articles (TEVA)

View Comments and Join the Discussion!